Cargando…
Immune- and Non-Immune-Mediated Adverse Effects of Monoclonal Antibody Therapy: A Survey of 110 Approved Antibodies
Identification of new disease-associated biomarkers; specific targeting of such markers by monoclonal antibodies (mAbs); and application of advances in recombinant technology, including the production of humanized and fully human antibodies, has enabled many improved treatment outcomes and successfu...
Autor principal: | Baldo, Brian A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8944650/ https://www.ncbi.nlm.nih.gov/pubmed/35323191 http://dx.doi.org/10.3390/antib11010017 |
Ejemplares similares
-
Monoclonal Antibodies Approved for Cancer Therapy
por: Baldo, Brian A.
Publicado: (2016) -
Adverse events to monoclonal antibodies used for cancer therapy: Focus on hypersensitivity responses
por: Baldo, Brian A
Publicado: (2013) -
Potential therapies for immune-related adverse events associated with immune checkpoint inhibition: from monoclonal antibodies to kinase inhibition
por: Henderson Berg, Meagan-Helen, et al.
Publicado: (2022) -
Monoclonal Antibody Therapy and Renal Transplantation: Focus on Adverse Effects
por: Zaza, Gianluigi, et al.
Publicado: (2014) -
Adverse Events of Monoclonal Antibodies Used for Cancer Therapy
por: Guan, Mei, et al.
Publicado: (2015)